PURPOSE OF REVIEW: This article reviews recent developments in the use of active surveillance for localized prostate cancer. RECENT FINDINGS: The treatment of localized prostate cancer continues to be a major challenge for urologic oncologists. Screening with prostate-specific antigen has resulted in increased numbers of low-risk prostate cancers being detected. Aggressive whole-gland therapy with surgery, or radiation therapy is associated with potentially life-altering treatment-related side effects such as urinary incontinence, bowel toxicity and erectile dysfunction. The goal of active surveillance is to avoid or delay the adverse events associated with prostate cancer therapy while still allowing for curative intervention in the future, if needed. SUMMARY: Active surveillance is a reasonable treatment option for many men with low-risk, and some men with intermediate-risk, prostate cancer. Additional research is needed to determine the optimal active surveillance inclusion criteria, monitoring schedule, and treatment triggers. It is hoped that advances in prostate imaging, biomarkers, and focal therapy will foster greater use of active surveillance in appropriately selected men to optimize quality-of-life without compromising cancer outcomes.
PURPOSE OF REVIEW: This article reviews recent developments in the use of active surveillance for localized prostate cancer. RECENT FINDINGS: The treatment of localized prostate cancer continues to be a major challenge for urologic oncologists. Screening with prostate-specific antigen has resulted in increased numbers of low-risk prostate cancers being detected. Aggressive whole-gland therapy with surgery, or radiation therapy is associated with potentially life-altering treatment-related side effects such as urinary incontinence, bowel toxicity and erectile dysfunction. The goal of active surveillance is to avoid or delay the adverse events associated with prostate cancer therapy while still allowing for curative intervention in the future, if needed. SUMMARY: Active surveillance is a reasonable treatment option for many men with low-risk, and some men with intermediate-risk, prostate cancer. Additional research is needed to determine the optimal active surveillance inclusion criteria, monitoring schedule, and treatment triggers. It is hoped that advances in prostate imaging, biomarkers, and focal therapy will foster greater use of active surveillance in appropriately selected men to optimize quality-of-life without compromising cancer outcomes.
Authors: Marco Auprich; Alexander Haese; Jochen Walz; Karl Pummer; Alexandre de la Taille; Markus Graefen; Theo de Reijke; Margit Fisch; Paul Kil; Paolo Gontero; Jacques Irani; Felix K-H Chun Journal: Eur Urol Date: 2010-07-03 Impact factor: 20.096
Authors: Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Susan T Stewart; Vibha Bhatnagar; Christopher J Sweeney; James E Stahl; Pamela M McMahon Journal: JAMA Date: 2010-12-01 Impact factor: 56.272
Authors: G Bartsch; W Horninger; H Klocker; A Reissigl; W Oberaigner; D Schönitzer; G Severi; C Robertson; P Boyle Journal: Urology Date: 2001-09 Impact factor: 2.649
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: R Choo; C Danjoux; G Morton; E Szumacher; L Sugar; S Gardner; M Kim; C M Choo; L Klotz Journal: Prostate Date: 2007-11-01 Impact factor: 4.104
Authors: William V Shappley; Stacey A Kenfield; Julie L Kasperzyk; Weiliang Qiu; Meir J Stampfer; Martin G Sanda; June M Chan Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: J Cuzick; G Fisher; M W Kattan; D Berney; T Oliver; C S Foster; H Møller; V Reuter; P Fearn; J Eastham; P Scardino Journal: Br J Cancer Date: 2006-11-06 Impact factor: 7.640
Authors: Shekoofeh Azizi; Sharareh Bayat; Pingkun Yan; Amir Tahmasebi; Guy Nir; Jin Tae Kwak; Sheng Xu; Storey Wilson; Kenneth A Iczkowski; M Scott Lucia; Larry Goldenberg; Septimiu E Salcudean; Peter A Pinto; Bradford Wood; Purang Abolmaesumi; Parvin Mousavi Journal: Int J Comput Assist Radiol Surg Date: 2017-06-20 Impact factor: 2.924
Authors: Alpay Özcan; Barış Türkbey; Peter L Choyke; Oguz Akin; Ömer Aras; Seong K Mun Journal: Magn Reson Imaging Date: 2015-04-11 Impact factor: 2.546
Authors: Patricia A Parker; John W Davis; David M Latini; George Baum; Xuemei Wang; John F Ward; Deborah Kuban; Steven J Frank; Andrew K Lee; Christopher J Logothetis; Jeri Kim Journal: BJU Int Date: 2015-04-21 Impact factor: 5.588
Authors: Michele Fascelli; Arvin K George; Thomas Frye; Baris Turkbey; Peter L Choyke; Peter A Pinto Journal: Curr Urol Rep Date: 2015-06 Impact factor: 3.092
Authors: Jacqueline Fontugne; Kristina Davis; Nallasivam Palanisamy; Aaron Udager; Rohit Mehra; Andrew S McDaniel; Javed Siddiqui; Mark A Rubin; Juan Miguel Mosquera; Scott A Tomlins Journal: Mod Pathol Date: 2016-01-08 Impact factor: 7.842